Latest Rhinology Stories
ANTONY, France, April 29 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite desensitization tablet. "We are very pleased with the outcome of this study, which is the first large study to ever demonstrate the efficacy of house dust mites allergen in treating perennial allergic rhinitis.
Children with allergies and asthma may benefit from an allergy evaluation, a U.S. allergist advises. Dr.
This exciting clinical study news is the best news that we have been waiting on for the past four years to prove the deposition of the medication through Sinus Dynamics. WESTLAKE VILLAGE, Calif., March 23 /PRNewswire/ -- Most ENTs and physicians who have prescribed Sinus Dynamics have always asked if it would be better to have a clinical study done on the amount of medication deposited and penetrated into the sinuses.
Saint Joseph Hospital Among the First to Offer New Surgical Treatment Approach CHICAGO, March 18 /PRNewswire/ -- After three years of suffering from congestion and several months of trying a steroid nasal spray, Chicago resident Matt Minella, 31, opted for a surgical procedure to help him breathe better through his nose.
Eliminates Need for Cadavers and Accelerates Physician Training GREAT BARRINGTON, Mass., March 17 /PRNewswire/ -- The Chamberlain Group, maker of anatomically accurate surgical training models, is improving how ENT physicians are trained using their new Maxillary Clinical Sinus Trainer.
ASTEPRO(TM) (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, N.J., Jan. 15 /PRNewswire/ -- This allergy season, a new medication is available to manage the symptoms of seasonal allergic rhinitis, a condition that impacts as many as 40 million people in the United States.
HARBIN, China, Dec. 16 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc.
Morria Biopharmaceuticals, a developer of anti-inflammatory drugs, has announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation.
LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis.
Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis.
In 1861 Adam Politzer of Vienna spent much time studying the air movement in the Eustachian tubes and the ear canal. He would measure the air movement by attaching a manometer, a very large gauge, to the ear canal and the pharynx. He developed an apparatus known as the Politzer bag in 1863 which is a less invasive way to clear the Eustachian tubes. Procedure Politzerization, also known as the Politzer maneuver, is a medical procedure which inserts air in the middle ear while the patient...
- An imitative word; an onomatopoetic word.